CLINICAL_TRIALS ClinicalTrials.gov record update

A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor a (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06031727
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:43.895320+00:00
Published At: 2025-03-17T00:00:00+00:00
Record Updated At: 2025-03-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neovascular Age-related Macular Degeneration(nAMD)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-17"
protocolSection.identificationModule.nctId: "NCT06031727"
protocolSection.identificationModule.officialTitle: "A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor a (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.